RT Book, Section
A1 Untch, Michael
A1 Minckwitz, Gunter von
A2 Kuerer, Henry M.
SR Print(0)
ID 6413437
T1 Chapter 48. The German Experience: Primary Systemic Therapy with Cytotoxic Agents
T2 Kuerer's Breast Surgical Oncology
YR 2010
FD 2010
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-160178-8
LK accesssurgery.mhmedical.com/content.aspx?aid=6413437
RD 2024/04/20
AB The  success  of  preoperative,  neoadjuvant  chemotherapy  for  locally  advanced  and  inflammatory  breast  cancer,  combined  with  emerging  data  on  the  use  of  adjuvant  chemotherapy,  led  to  the  evaluation  of  the  primary  systemic  therapy  (PST)  (neoadjuvant)  approach  for  women  with  primary  operable  breast  cancer.  Potential  advantages  of  PST  include  increasing  rates  of  breast  conservation,  reducing  mortality  with  lower  toxicity,  and  in  vivo  testing  of  sensitivity  of  cancer  cells  to  the  systemic  therapy  used.1